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Background: Enhancer of zeste homologue 2 (EZH2) is a polycomb group (PcG) family protein. Acting as a histone
methyltransferase it plays crucial roles in maintaining epigenetic stem cell signature, while its deregulation leads to
tumor development. EZH2 overexpression is commonly associated with poor prognosis in a variety of tumor types
including carcinomas, lymphomas and soft tissue sarcomas. However, although the synovial sarcoma fusion
proteins SYT-SSX1/2/4 are known to interact with PcG members, the diagnostic and prognostic significance of
EZH2 expression in synovial sarcoma has not yet been investigated. Also, literature data are equivocal on the
correlation between EZH2 expression and the abundance of trimethylated histone 3 lysine 27 (H3K27me3) motifs in
tumors.
Methods: Immunohistochemical stains of EZH2, H3K27me3, and Ki-67 were performed on tissue microarrays
containing cores from 6 poorly differentiated, 39 monophasic and 10 biphasic synovial sarcomas, and evaluated by
pre-established scoring criteria. Results of the three immunostainings were compared, and differences were sought
between the histological subtypes as well as patient groups defined by gender, age, tumor location, the presence
of distant metastasis, and the type of fusion gene. The relationship between EZH2 expression and survival was
plotted on a Kaplan-Meier curve.
Results: High expression of EZH2 mRNA and protein was specifically detected in the poorly differentiated subtype.
EZH2 scores were found to correlate with those of Ki-67 and H3K27me3. Cases with high EZH2 score were
characterized by larger tumor size (≥ 5cm), distant metastasis, and poor prognosis. Even in the monophasic and
biphasic subtypes, higher expression of EZH2 was associated with higher proliferation rate, larger tumor size, and
the risk of developing distant metastasis. In these histological groups, EZH2 was superior to Ki-67 in predicting
metastatic disease.
Conclusions: High expression of EZH2 helps to distinguish poorly differentiated synovial sarcoma from the
monophasic and biphasic subtypes, and it is associated with unfavorable clinical outcome. Importantly, high EZH2
expression is predictive of developing distant metastasis even in the better-differentiated subtypes. EZH2
overexpression in synovial sarcoma is correlated with high H3K27 trimethylation. Thus, along with other epigenetic
regulators, EZH2 may be a future therapeutic target.
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Synovial sarcoma, an aggressive soft tissue tumor with
high rate of local recurrence and distant metastasis, is
currently thought to originate from mesenchymal stem
cells [1]; hence, the traditional term ‘synovial’ is a mis-
nomer. Synovial sarcomas occur most commonly in young
patients, representing about 10% of soft tissue sarcomas in
all age groups and about 15-20% in adolescents, with
more than 80% of the cases arising in deep soft tissues
around large joints or tendons. Synovial sarcomas can dis-
play monophasic (MPSS), biphasic (BPSS) and poorly dif-
ferentiated (PDSS) histology, with the latter accounting
for approx. 10% of the cases. PDSS is defined by high cel-
lularity, high nuclear grade, and high mitotic activity, as
well as areas of necrosis. Its morphology is typically domi-
nated by small round cells or rhabdoid-like cells similar to
undifferentiated embryonic cells, and its clinical course
tends to be aggressive with early recurrence and metasta-
sis [2,3].
Enhancer of zeste homologue 2 (EZH2) is a member of
the polycomb group (PcG) protein family. The PcG family
consists of epigenetic transcriptional repressors which
participate in cell cycle regulation, DNA damage repair,
cell differentiation, senescence, and apoptosis. PcG regula-
tion is known to be involved in the maintenance of stem
cell signature, but also in tumor development [4]. Specifi
cally, EZH2 acts as a histone methyltransferase targeting
the N-terminal tail of histone 3 and producing a cha-
racteristic trimethylated H3-Lys27 (H3K27me3) motif. It
shows high expression in cells possessing embryonic gene
expression signature, while its amount declines with tissue
maturation and differentiation [5]. Abnormal overexpres-
sion of EZH2 has been reported in a wide variety of tumor
types including carcinomas, lymphomas, cutaneous me-
lanoma, and soft tissue sarcomas [6]. High expression of
EZH2 is generally associated with advanced stages of tu-
mor progression, aggressive tumor behavior, and dismal
clinical outcome [7].
Intriguing hypotheses have recently been formula-
ted on the collaboration between EZH2 and SYT-SSX,
the chimeric gene diagnostic of synovial sarcoma. The
chromosomal translocation t(X;18)(p11;q11) can be de-
monstrated in over 95% of cases by fluorescence in situ
hybridization (FISH) or real-time PCR (RT-PCR) and
produces one of the fusion genes SYT-SSX1, SYT-SSX2
or, rarely, SYT-SSX4 [1,8]. Due to its intranuclear lo-
calization but lack of a chromatin binding domain, SYT-
SSX is thought to modify gene expression by associa-
ting with sequence-specific DNA-binding proteins [9].
SYT has been described to interact with transcription-
enhancing trithorax group proteins such as the SWI/
SNF chromatin remodeling complexes via its SNH do-
main, while SSX has been shown to bind with the
transcription-silencing PcG proteins such as EZH2 viaits SSXRD domain. SYT-SSX is hypothesized to bring to-
gether these oppositely acting protein complexes, allo-
wing each to make its contribution to sarcomatogenesis
[10,11]. Identification of possible target genes influenced
by this epigenetic deregulation has begun, but much ef-
fort is still needed to elucidate the pathomechanism in
full detail [12].
Although high EZH2 expression was shown to be
generally associated with poor prognosis in soft tissue
sarcomas [13], neither differential expression of EZH2 in
the various histological subtypes of synovial sarcoma nor
the association of EZH2 with H3K27 trimethylation,
tumor behavior, and clinical parameters has been in-
vestigated in this particular tumor type. Therefore, a tis-
sue microarray-based immunohistochemical study was
designed to address these points. Since synovial sarcoma
patients are divided into low-risk and high-risk prognos-
tic groups based on age (younger or older than 25 years),
tumor size (larger or smaller than 5 cm), mitotic activi-
ty, and the presence or absence of poorly differentiated
areas [3,14], correlations were sought between EZH2 ex-
pression and these prognostic factors, as well as with
other clinical data such as gender, tumor location, dis-
tant metastasis, and the type of fusion gene which also
has been reported to impact disease outcome [15]. The
impact of EZH2 expression on overall survival was ana-
lyzed on a Kaplan-Meier curve. EZH2 expression was
also measured at the mRNA level by quantitative real-
time PCR (qRT-PCR) to support the immunohistoche-
mical findings.
Methods
Tissue specimens and microarrays
We constructed TMAs containing duplicates of 6-mm
cores from 55 cases of previously diagnosed synovial sar-
coma. Our samples included 6 PDSS, 39 MPSS, and 10
BPSS tissues fixed in 10% formalin and embedded in
paraffin. Tumor tissues were selected from the archives
of the 1st Department of Pathology and Experimen-
tal Cancer Research, Semmelweis University, Budapest,
Hungary, from the years between 1996 and 2009, and
sampled by anexpert soft tissue pathologist (Z.S.). The
patients gave informed consent to the research purpose
use of their tissue. Only primary tumors without pre-
operative chemo- or radiotherapy were chosen. Clinical
data (age, gender, tumor location, tumor size, presence
or absence of metastases and the type of the fusion
gene) were obtained from the institutional records.
Clinical follow-up data were also available for 32 cases
(time after operation: 8–162 months). Pathological diag-
noses were made according to the World Health Or-
ganization (WHO) classification [2], and confirmed by
either FISH or RT-PCR. The research was conducted in
concordance with the Institutional Ethical Guidelines.
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Figure 1 Photomicrographs representing the scores 0, 3, and 6
for EZH2, H3K27me3, and Ki-67 immunostaning.
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After preparing 4-μm cuts from the formalin-fixed,
paraffin-embedded TMAs, sections were deparaffinized in
xylene and rehydrated in a descending ethanol series.
Antigen retrieval was achieved by using either Bond Epi-
tope Retrieval Solution 1 (pH~6) or Bond Epitope Re-
trieval Solution 2 (pH~9) (Leica Microsystems, Wetzlar,
Germany) at 99–100°C for 20–30 minutes. Monoclonal
mouse anti-EZH2 (1:25, clone 11, BD Biosciences,
USA), monoclonal rabbit anti-trimethyl-Histone H3
Lys27 (1:200, clone C36B11, Cell Signaling Technology,
USA), or monoclonal mouse anti-Ki-67 (1:50, clone
MIB-1; Dako, Denmark) antibodies were applied on the
slides. Immunohistochemical staining was performed
on a Leica BOND-MAX™ autostainer (Leica Microsys-
tems, Berlin, Germany), and peroxidase/DAB Bond™
Polymer Refine Detection System (Leica Microsystems)
was used for visualization.
Scoring system
To assess the immunohistochemical labeling of EZH2,
H3K27me3, and Ki-67, immunostained slides were
evaluated under a 10x magnification objective. Nuclear
staining intensity was scored as follows: 0, no visible
staining; 1, weak; 2, moderate; 3, strong. Higher score
was chosen if at least 30% of positive tumor cells showed
stronger intensity. To quantify the extent of immunos-
taining, the percentage of tumor cells with positive nu-
clear reaction was counted, and a score was assigned as
follows: 0, no visible staining; 1, 1–50%; 2, 51–75%; 3,
over 75%. Each core contained at least 100 tumor cells
to be evaluated. The two scores were summed to yield a
final score ranging from 0 to 6. Fields of view represen-
tative of scores 0, 3, and 6 are shown in Figure 1. A total
score ≤ 3 was defined as low and ≥ 4 as high.
Analysis of EZH2 mRNA expression
For EZH2 gene expression analysis, total RNA was iso-
lated from formalin-fixed, paraffin-embedded blocks of
synovial sarcoma tissue by using RecoverAll™ Total Nu-
cleic Acid Isolation Kit (Ambion, Austin, USA). The qua-
lity of isolated RNA was adequate for gene expression
analysis in 13 MPSS, 2 BPSS and 6 BPSS cases. cDNA was
generated from 1 μg of total RNA using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, USA), following the instructions of the sup-
plier. Quantitative real-time PCR (qRT-PCR) was per-
formed in a LightCycler 480 Real-Time PCR System
(Roche Applied Science, Indianapolis, USA) by using ABI
TaqMan Gene Expression Assay for human EZH2 gene
(assay ID: Hs01016789_m1; Applied Biosystems) accor-
ding to the manufacturer’s protocol. The expression of
EZH2 was normalized to endogenous human riboso-
mal protein S18 (assay ID: Hs02387368_g1; AppliedBiosystems), and cDNA from lymph node served as ca-
librator. Results were obtained as crossing point (Cp)
values. Expression levels were calculated by using the
2-ΔΔCp method.
Statistical analysis
Prism 4 software (GraphPad, USA), SigmaPlot and Sigma-
Stat software packages (SPSS, version 11.0, IBM, USA)
and the VassarStats website (www.vassarstats.net) were
used for statistical analyses. Kruskal-Wallis test was used
for the comparison of more than two groups, while pair-
wise comparison of non-Gaussian data sets was done by
the Mann–Whitney test. Correlations were analyzed by
the Spearman’s rank order correlation test (Spearman's
rho, ρ) and coefficient of determination (R2). Kaplan-
Meier curves were created based on the duration of sur-
vival after operation, and groups were compared with uni-
variate analysis using the log-rank test. For all analyses,
P values <0.05 were considered as statistically significant.
Results
Clinical data
The clinical characteristics of our 55 synovial sarcoma
cases and the results of immunostaining are summarized
in Additional file 1: Table S1. Six tumors were classi-
fied histologically as poorly differentiated, while 39 were
described as monophasic and 10 as biphasic. The num-
bers of male and female patients were 31 and 24, res-
pectively. Age younger than 25 years was recorded in 8
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mean age was 47 (range, 18–79). The tumor was located
on the periphery in 39 cases and centrally in 16 cases.Figure 2 Distribution of scores 0–6 in the MPSS, BPSS, and
PDSS subtypes, shown as stacked columns (A). mRNA expression
of EZH2 in the PDSS vs. MPSS+BPSS groups, mean ± S.D. Human
ribosomal protein S18 was used as endogenous control and human
lymph node was served as calibrator.Tumors were larger than 5 cm in 14 cases. Distant me-
tastasis was present in 31 cases. There were 35 cases
associated with SYT-SSX1 fusion gene and 20 cases with
SYT-SSX2.
High expression of EZH2 and high abundance of
H3K27me3 in PDSS
Percent distribution of immunohistochemical scores is
illustrated in Figure 2A, and statistical results are summa-
rized in Table 1. Similar to Ki-67, high immunohistoche-
mical scores of EZH2 and H3K27me3 were specifically
recorded in PDSS and only rarely in the other subtypes.
Overexpression of EZH2 in PDSS relative to MPSS and
BPSS (8.1x higher expression in PDSS, P<0.001) was also
confirmed at the mRNA level (Figure 2B). Significant dif-
ferences between PDSS, MPSS and BPSS for EZH2,Table 1 Comparison of immunohistochemical scores
across patient groups sorted by histological subtype or
clinical / molecular characteristics
Compared groups Statistical test used Result
EZH2
PDSS and MPSS and BPSS Kruskal-Wallis P < 0.001
PDSS vs. MPSS Mann–Whitney P < 0.001
PDSS vs. BPSS Mann–Whitney P = 0.001
MPSS vs. BPSS Mann–Whitney NS
H3K27me3
PDSS and MPSS and BPSS Kruskal-Wallis P < 0.001
PDSS vs. MPSS Mann–Whitney P < 0,001
PDSS vs. BPSS P = 0.001
MPSS vs. BPSS Mann–Whitney NS
Ki-67
PDSS and MPSS and BPSS 1 P < 0.001
PDSS vs. MPSS Mann–Whitney P < 0,001
PDSS vs. BPSS Mann–Whitney NS
Compared groups EZH2 Ki-67 H3K27me3
Gender
Male vs. female NS NS NS
Age
≤25 y/o vs. >25 y/o NS NS NS
Location
Central vs. peripheral NS NS NS
Tumor size
<5cm vs. ≥5cm P < 0.001 NS P = 0.032
Distant metastasis
Present vs. absent P < 0.001 P = 0.021 P = 0.003
Fusion gene
SYT-SSX1 vs. SYT-SSX2 NS NS NS
(PDSS: poorly differentiated synovial sarcoma; MPSS: monophasic synovial
sarcoma; BPSS: biphasic synovial sarcoma; NS: not significant).
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detected by Kruskal-Wallis test (all P<0.001). The mean
scores of all three markers were significantly higher in
PDSS as compared with MPSS and BPSS. Furthermore,
scores of EZH2 and H3K27me3, but not of Ki-67, were
significantly higher in patients with larger tumor size, and
all three markers were significantly higher in those with
distant metastasis (Table 1). No statistically significant
differences in mean immunohistochemical scores were
found with regard to clinical factors such as age, gender,
tumor location, or the type of fusion gene. Thus, EZH2
and H3K27me3 may be regarded as auxiliary markers of
the poorly differentiated subtype, although the potential of
EZH2 and H3K27me3 immunostaining to discriminate
between PDSS and the other subtypes was inferior to that
of Ki-67 (sensitivities, specificities, and positive predictive
values for EZH2: 1.00, 0.82, 0.4; H3K27me3: 1.00, 0.90,
0.54; Ki-67, 1.00, 0.96, 0.75, respectively).
Across all subtypes, EZH2 expression was found to
correlate with the abundance of H3K27me3 motifs
(Figure 3A, ρ: 0.73, P<0.0001, R2=0.648), indicating causal
relationship between EZH2 activity and the presence of
the associated epigenetic marker in synovial sarcoma. Sig-
nificant positive correlation could also be demonstrated
between EZH2 and Ki-67 scores both when including all
cases (Figure 3B, ρ: 0.65, P<0.0001, R2=0.519) and with
the exclusion of PDSS cases (Figure 3C, ρ: 0.50, P<0.001,
R2=0.242), suggesting that EZH2 expression and pro-
liferative activity were positively linked in the better-
differentiated subtypes as well.
EZH2 as a potential prognostic marker in synovial
sarcoma
Kaplan-Meier curves generated by separating patients
on the basis of high versus low EZH2 and H3K27me3
scores were similar to the one based on Ki-67 scoreFigure 3 Scatter graphs with linear trend lines indicate positive corre
included in (A) and (B), while PDSS patients were excluded in (C). Spearma
bottom.(Figure 4). However, Ki-67 was a superior predictor of
tumor-associated death, since the hazard ratios referring
to high EZH2, H3K27me3, and Ki-67 expression were
4.48, 5.65, and 6.32, respectively. Nevertheless, high
EZH2 score also proved to be a valuable predictor of
disease outcome, since it was significantly associated
with larger tumor size and the presence of distant me-
tastasis. Moreover, these associations held true not only
in the entire patient population but also after the exclu-
sion of PDSS cases. In contrast, high H3K23me3 failed
to show such associations, and high Ki-67 was associated
with larger tumor size in all patients only (Table 2) indi-
cating that EZH2 may be useful in the stratification of
MPSS and BPSS patients into low and high risk prog-
nostic groups with respect to the likelihood of develop-
ing distant metastasis.
Discussion
In our study, high expression of EZH2 was predomi-
nantly found in the poorly differentiated histological
subtype of synovial sarcoma, which was associated with
aggressive clinical behavior. High levels of EZH2 were
shown to be associated with poor clinical outcome in
other tumor types as well, and the mechanisms that
link EZH2 activity with tumor progression are gradual-
ly being unfolded [7]. Yet the exact causes and conse-
quences of EZH2 overexpression in PDSS remain to be
clarified. With regard to its transcriptional regulation, a
hypothetic role can be assigned to MYC, since recent
gene expression profiling data revealed up-regulation of
genes located on chromosome 8q, including MYC, in
PDSS [16], and MYC has been reported to induce EZH2
in prostatic carcinoma [17]. EZH2 expression may also
be triggered by hypoxia, a condition present in nearly all
solid tumors: HIF1α-dependent transactivation of EZH2
was demonstrated in breast cancer-initiating cells [18].lations between EZH2 and the other markers. All patients were
n’s r (ρ) and coefficient of determination (R2) values are shown at the
Figure 4 Kaplan-Meier survival curves for high vs. low EZH2, HeK27me3, and Ki-67 score. Hazard ratios (HR) of the high-score groups with
95% confidence intervals are shown at the bottom.
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FLI1 fusion protein in Ewing’s sarcoma suggests that
translocation-associated chimeric proteins may also play
a regulatory role [19]. At the post-transcriptional level,
microRNAs are likely to modulate EZH2 levels, sinceTable 2 Association of high EZH2, H3K27me3, and Ki-67
scores with the risk of large tumor size and distant
metastasis (NS: non-significant)
Relative
Risk
95% Confidence
Interval
P value
High EZH2 score
All Cases
-Tumor size >5 cm 4.09 1.78-9.40 P<0.001
-Distant metastasis 2.20 1.49-3.23 P<0.001
Cases other than PDSS
-Tumor size >5 cm 4.00 1.63-9.82 P=0.02
-Distant metastasis 2.09 1.36-3.21 P=0.02
High H3K27me3 score
All Cases
-Tumor size >5 cm 2.25 1.07-4.73 NS
-Distant metastasis 1.64 1.09-2.46 NS
Cases other than PDSS
-Tumor size >5 cm 1.12 0.20-6.17 NS
-Distant metastasis 1.20 0.55-2.60 NS
High Ki-67 score
All Cases
-Tumor size >5 cm 2.62 1.29-5.34 P=0.04
-Distant metastasis 1.71 1.17-2.51 NS
Cases other than PDSS
-Tumor size >5 cm 1.75 0.39-7.88 NS
-Distant metastasis 0.98 0.24-4.03 NSEZH2 is a validated target of the promyogenic miR-26a,
and high expression of EZH2 was consistently paralleled
by suppression of miR-26a in rhabdomyosarcoma [20].
Once overexpressed, EZH2 places epigenetic marks
that prevent RNA polymerase II-dependent transcrip-
tional elongation and lead to silencing of the down-
stream genes. PcG family members are arranged into
multimeric polycomb repressive complexes (PRC), and
EZH2 is a core member and catalytic unit of PRC2.
H3K27me3 produced by PRC2 is recognized by PRC1
which, in turn, monoubiquitylates lysine 119 of histone
H2A. PRC2 also interacts with other repressive epige-
netic modifiers such as histone deacetylases (HDAC)
and DNA methyltransferases (DNMT) which promote
chromatin condensation [7,21,22]. Remarkably, the bind-
ing of PRC1 hinders the access of other chromatin remod-
eling complexes such as SWI/SNF that may have
transcription-enhancing functions [23], which implies that
out of the antagonistic partners of SYT-SSX in synovial
sarcoma, CpG may ultimately dominate over SWI/SNF
[10].
Although the target genes of EZH2-mediated silencing
in synovial sarcoma still wait to be identified, EZH2 ac-
tivity is generally thought to favor the conservation of
undifferentiated state and give way to rapid proliferation.
Significantly overlapping sets of genes were found to be
targeted by PRC2 in prostatic carcinoma and embryonic
cells, and repression of these genes was associated with
poor clinical outcome [24]. EZH2 is therefore believed
to drive tumor cells into a more aggressive, embryo-
nic stem-like state, as it is clearly exemplified by EZH2-
overexpressing tumors with embryonic morphology like
rhabdomyosarcoma or Ewing’s sarcoma [25]. EZH2 also
facilitates cell cycle progression: its expression is induced
by E2F, a chief coordinator of mitotic entry, while EZH2
itself represses, among others, the tumor suppressor
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Our findings indicate that the link between EZH2 expres-
sion, high mitotic activity, and undifferentiated morpho-
logy exists in synovial sarcoma as well, since EZH2 scores
strongly correlated with those of Ki-67 and were highest
in poorly differentiated tumors.
Another positive correlation found in our study, namely
the one between EZH2 expression and the abundance of
H3K27me3 motifs, could be logically expected from the
catalytic activity EZH2 is known to exert in PRC2. The ac-
tivating somatic mutation Y641 of EZH2 leads to high
H3K27 trimethylation in lymphomas [28,29], and high
levels of H3K27me3 consequent to EZH2 hyperactivity
have been reported in hepatocellular carcinoma and
esophageal squamous cell carcinoma [30,31]. It is all the
more intriguing why in certain tumors, such as carcinomas
of the breast, ovary, and pancreas, no clear correlation be-
tween EZH2 expression and H3K27 trimethylation was
found; rather, quite counterintuitively, both high EZH2 and
low H3K27me3 turned out to have adverse prognostic sig-
nificance [32]. Explanations proposed for this apparent dis-
crepancy include the disruption of PRC2 by overproduced
EZH2, the formation of tumor-specific PRCs with different
histone substrate specificity, and Akt-mediated inhibitory
phosphorylation of EZH2 [32-34].
By examining associations between EZH2 expression,
histological subtype, and clinical factors such as tumor
characteristics and disease course, we wished to clarify
whether EZH2 (and/or H3K27me3) immunohistochemis-
try may provide any additional diagnostic, prognostic, or
therapeutic information that cannot be deduced from
other data. The markers investigated herein showed
significant association with histology and distant metasta-
sis, but varied independently from other clinical factors
and the type of fusion gene. EZH2 and H3K27me3 scores
also exhibited significant association with tumor size.
Although Ki-67 distinguished more accurately between
PDSS and the better-differentiated subtypes, both high
EZH2 and high H3K27me3 were preferentially associated
with PDSS. Further, whereas Ki-67 as a well-established
prognostic marker in soft tissue sarcomas proved to be a
superior predictor of overall survival [35], high EZH2
status – but not high H3K27me3 or high Ki-67 – was
found to be predictive of distant metastasis in the MPSS
+BPSS group. Thus, while not sufficiently specific when
applied alone, both EZH2 and H3K27me3 can be used as
auxiliary immunohistochemical markers of the poorly
differentiated subtype in doubtful cases (e.g., better-
differentiated histomorphology coupled with high mitotic
rate, or vice versa). Moreover, EZH2 status, along with
other recently proposed factors such as ploidy [36], may
refine the current stratification of MPSS and BPSS
patients into low- and high-risk subgroups, thus influen-
cing prognosis and possibly also the therapeutic decisions.Lastly, EZH2 as a highly expressed pro-oncogenic re-
gulator may also be an attractive candidate target for the
future therapy of synovial sarcoma. SYT-SSX closely colla-
borates with both EZH2 and HDAC in the repression
of the tumor suppressor early growth response 1 (EGR1)
[10]. Romidepsin (FK228), a HDAC inhibitor, reactivated
EGR1 expression and caused tumor shrinkage in a
preclinical synovial sarcoma model, presumably by
disrupting the interactions within this complex [12,37]. It
is reasonable to assume that concomitant inhibition of
HDAC and EZH2 might yield a synergistic effect. Success-
ful repression of EZH2 was achieved by small interfering
RNA (siRNA) as well as using the small-molecule
pharmacologic inhibitor 3-deazaneplanocin A in neuro-
blastoma cells . Translation of these results into the treat-
ment of synovial sarcoma may open novel therapeutic
[38]opportunities.
Conclusion
High expression of EZH2 helps to distinguish poorly dif-
ferentiated synovial sarcoma from the monophasic and
biphasic subtypes, and it is associated with unfavorable
clinical outcome. Importantly, high EZH2 expression is
predictive of developing distant metastasis even in the
better-differentiated MPSS and BPSS subtypes. EZH2
overexpression in synovial sarcoma is correlated with
high H3K27 trimethylation, indicating a functional partici-
pation of EZH2 in PRC2. In summary, EZH2 can be used
as an auxiliary diagnostic and prognostic marker in the
histopathologic evaluation of synovial sarcoma in addition
to the markers currently in use. Later, overexpressed
EZH2 may become a therapeutic target in synovial
sarcoma, especially when inhibited in combination with
other pro-oncogenic epigenetic modulators.
Additional file
Additional file 1: Table S1. Clinical data, immunohistochemical scores,
and EZH2 gene expression values of 55 synovial sarcoma cases. Legend:
gender: M: male; F: female; size: 0, <5cm; 1, ≥5cm; location: P, peripheral;
C: central; end point: 1, deceased; 0, alive at the indicated time point
(months post op.); NA: data not available.
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deacetylase; MPSS: Monophasic synovial sarcoma; PcG: Polycomb group;
PDSS: Poorly differentiated synovial sarcoma; PRC: Polycomb repressor
complex; qRT-PCR: Quantitative real time- polymerase chain reaction;
siRNA: Small interfering RNA.
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